Skip to main content
. Author manuscript; available in PMC: 2018 Apr 8.
Published in final edited form as: Cell Metab. 2016 Oct 13;24(5):728–739. doi: 10.1016/j.cmet.2016.09.005

Figure 1. Altered mitochondrial metabolism in human ovarian tumors from patients taking metformin.

Figure 1

A. Extracted ion chromatogram of authentic standard metformin (top) and metformin extracted from mouse serum (bottom) with an m/z window of 6 ppm (+/− 3ppm). MS2 spectrum of authentic metformin (top) and metformin extracted from mouse serum (bottom). B. Metformin levels in serum of ovarian cancer (OvCa) patients. C. Metformin concentration in ovarian tumors from patients. D. Insulin levels in the serum of OvCa patients after overnight fasting. E. Metabolites with trending changes (p<0.1, * p<0.05, ** p<0.01, student’s t-test two tailed) in tumors from patients on metformin compared to tumor not exposed to metformin treatment (N=10). The fold change is calculated by dividing MS intensity (integrated peak area of metabolites) values of each metabolite in metformin treated patient tumors by those with no metformin treatment. Error bars obtained from SEM of n=10 independent measurements.